A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS) (DSS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01461005 |
Recruitment Status :
Terminated
(FDA reclassified so all 522 studies were stopped,)
First Posted : October 27, 2011
Results First Posted : October 15, 2019
Last Update Posted : February 19, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Spondylolisthesis Neurologic Deficits Kyphosis Pseudarthrosis | Device: Dynamic Stabilization System (DSS) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System(DSS) |
Study Start Date : | September 2011 |
Actual Primary Completion Date : | September 2016 |
Actual Study Completion Date : | September 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Dynamic Stabilization System
Dynamic Stabilization System (DSS) System
|
Device: Dynamic Stabilization System (DSS)
Dynamic Stabilization System |
- Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure. [ Time Frame: 6 months ]The safety endpoint is defined as the incidence of serious or device related adverse events attributable to the device or procedure. Reoperations, revisions or removals of the Dynamic Stabilization System (DSS) System implant will be evaluated.
- Measurement of Lower Back Pain as Assessed by Visual Analog Scale [ Time Frame: 6 months ]Lower back pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)
- Measurement of Right Leg Pain as Assessed by Visual Analog Scale [ Time Frame: 6 months ]Right leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)
- Measurement of Left Leg Pain as Assessed by Visual Analog Scale [ Time Frame: 6 months ]Left leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)
- Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline. [ Time Frame: Pre-Op, 6 weeks, 6 months, 12 months, and 24 months ]The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 "worst imaginable health state" to 100 "best imaginable health state".
- Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI). [ Time Frame: 6 months ]ODI is a questionnaire that provides information on back and the affects on managing every day life by diving questions into 10 sections. The total possible score for each section is 0-5. The scores are then converted into percentages ranging from 0% (minimal disability) to 100% (maximum possible disability).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient is skeletally mature (21-85 years old).
- Patient has degenerative spondylolisthesis (Grade 1-3) with objective evidence of neurologic impairment, kyphosis, and/or failed previous fusion (pseudarthrosis) at index level.
- Capable and willing to comply with the requirements unique to the study, adhere to the post-operative treatment and management program, and return for required follow-up examinations.
- Surgeon has determined that DSS™ System is an appropriate treatment for the patient without regard to the study.
Exclusion Criteria:
- The need for interbody cages, allograft, or any other assistance during surgery. Device is only to be used with autograft per FDA approved indications.
- Any medical, mental or surgical condition precluding the potential benefit of spinal surgery or surgery in general.
- Acute or chronic systemic, spinal or localized infections.
- Active, severe systemic and metabolic diseases.
- Obesity defined as Body Mass Index > 35.
- Subject is pregnant or interested in becoming pregnant in the next 36 months.
- Dependency on pharmaceutical drugs, drug abuse, or alcoholism.
- Lack of patient cooperation.
- Foreign body sensitivity to the implant material.
- Degenerative scoliosis greater than 25 degrees.
- Grade 4 degenerative spondylolisthesis (>75% slip).
- Significant osteopenia A screening questionnaire for osteopenia, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA bone mineral density measurement. If DEXA is required*, exclusion will be defined as a DEXA bone density measured T score of ≤ -1.0 (The World Health Organization definition of osteopenia).
- Soft tissue deficit not allowing wound closure.
- Congenital abnormalities, tumors or other conditions that would prevent secure component fixation that has the potential to decrease the useful life of the device.
- Inadequate pedicles or vertebral body geometry of the thoracic, lumbar and sacral vertebrae.
- Bony lumbar spinal stenosis not related to the primary degenerative spondylolisthesis indication.
- Pars defect.
- Clinically compromised vertebral bodies at affected level due to current or past trauma.
- Prisoner or ward of the state.
- Currently in litigation regarding a spinal condition.
- Known allergy to titanium, titanium alloys, CoCrMo, polyethylene or MR contrast agents.
- Is currently involved in a study of another investigational product for similar purpose.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01461005
United States, California | |
University of California, Davis Medical Center | |
Sacramento, California, United States, 95816 |
Study Director: | Gitela Gandelman | Paradigm Spine LLC |
Responsible Party: | Paradigm Spine |
ClinicalTrials.gov Identifier: | NCT01461005 |
Other Study ID Numbers: |
Dynamic Stabilization System |
First Posted: | October 27, 2011 Key Record Dates |
Results First Posted: | October 15, 2019 |
Last Update Posted: | February 19, 2020 |
Last Verified: | February 2020 |
Spondylolisthesis Neurologic impairment Kyphosis Pseudarthrosis |
Spondylolisthesis Kyphosis Neurologic Manifestations Pseudarthrosis Spondylolysis Spondylosis Spinal Diseases |
Bone Diseases Musculoskeletal Diseases Spinal Curvatures Fractures, Ununited Fractures, Bone Wounds and Injuries Nervous System Diseases |